看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
1 p' X# j+ y9 f- h4 q* W+ A0 A
+ j& C. P) [) s2 s& S3 s" m2 d7 \
* c% y5 u/ i/ k7 P6 {- jCurrently available feasibility data for possible combination strategies.
5 {5 H7 g! K) b. D2 y h+ O7 H4 S& A————————————————————————————————! B: W5 K5 K7 J% D1 D: y6 m
Combination Feasibility according to preliminary data / X0 g8 m3 M+ U3 X- \& n$ Z# w6 I0 z
——————————————————————————————————& M2 m8 g0 d7 G; k* F
Bevacizumab + sorafenib Yes, reduced dose
! N. h) M! I6 L: WBevacizumab + sunitinib† No
" K* K' d% h4 L' Y2 y8 hBevacizumab + temsirolimus Yes + t% C6 R1 u' a1 w& r7 L" \/ X
Bevacizumab + everolimus Yes
3 A- X, h2 g$ y o4 }8 xSorafenib + sunitinib ?
/ Z+ t; ~) y' |* P: N! hSorafenib + temsirolimus Yes, reduced dose
6 }: E* R7 @8 |: y" MSorafenib + everolimus Yes, reduced dose " u# i. @4 e/ R* z2 I7 c
Sunitinib + temsirolimus† No
; C$ c6 g# d* x" L/ v% k1 F' Q2 [4 T/ tSunitinib + everolimus ?
. V0 Y N. u3 I) qTemsirolimus + everolimus ? % e- ^9 |3 C6 \( m2 _ e9 h5 P' k: \
————————————————————, L, ^. m- J3 Q; s: X0 v
†Led to US FDA warning.1 V7 u0 G: O8 u2 j- d6 H% P) c, [" [
?: As yet unattempted combination.4 W" ^8 s' y$ X: |. k! d
|